Nyxoah SA Logo

Nyxoah SA

ISIN: BE0974358906 | Ticker: NYXH | LEI: 5493002O1ESKZ18OXR80
Sector: Health CareSub-Industry: Health Care Equipment
Country: Belgium

About Nyxoah SA

Company Description

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).

Nyxoah’s lead solution platform is based on the Genio® system, a CE-Mark validated, patient-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk* and comorbidities including cardiovascular diseases, depression and stroke.

Year founded

2009

Served area

Worldwide

Headquarters

Rue Edouard Belin 12, 1435 Mont-Saint-Guibert – Belgium

Financial statements

Download as Excel
Line item in (eur) 02.01.2020 01.01.2021 02.01.2021 01.01.2022
Assets N/A 114,080,000.00 N/A 170,830,000.00
Noncurrent Assets N/A 19,972,000.00 N/A 30,770,000.00
Property Plant And Equipment N/A 713,000.00 N/A 2,020,000.00
Intangible Assets Other Than Goodwill N/A 15,853,000.00 N/A 25,322,000.00
Noncurrent Receivables N/A 91,000.00 N/A 164,000.00
Deferred Tax Assets N/A 32,000.00 N/A 46,000.00
Current Assets N/A 94,108,000.00 N/A 140,060,000.00
Inventories N/A 55,000.00 N/A 346,000.00
Current Trade Receivables N/A 0.00 N/A 226,000.00
Cash and cash equivalents 5,855,000.00 92,300,000.00 92,300,000.00 135,509,000.00
Other Current Assets N/A 109,000.00 N/A 1,693,000.00
Equity And Liabilities N/A 114,080,000.00 N/A 170,830,000.00
Equity N/A 97,190,000.00 N/A 148,622,000.00
Issued Capital N/A 3,796,000.00 N/A 4,427,000.00
Retained Earnings N/A -60,341,000.00 N/A -87,167,000.00
Share Premium N/A 150,936,000.00 N/A 228,033,000.00
Reserve Of Sharebased Payments N/A 2,650,000.00 N/A 3,127,000.00
Liabilities N/A 16,890,000.00 N/A 22,208,000.00
Noncurrent Liabilities N/A 10,488,000.00 N/A 10,636,000.00
Noncurrent Provisions N/A 0.00 N/A 12,000.00
Deferred Tax Liabilities N/A 0.00 N/A 5,000.00
Other Noncurrent Financial Liabilities N/A 7,607,000.00 N/A 7,802,000.00
Noncurrent Recognised Liabilities Defined Benefit Plan N/A 37,000.00 N/A 80,000.00
Current Liabilities N/A 6,402,000.00 N/A 11,572,000.00
Other Current Payables N/A 4,123,000.00 N/A 3,633,000.00
Current Tax Liabilities Current N/A 0.00 N/A 2,808,000.00
Other Current Financial Liabilities N/A 616,000.00 N/A 554,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
Revenue From Sale Of Goods 69,000.00 852,000.00
Profit Loss From Operating Activities -11,224,000.00 -26,242,000.00
Finance Income 62,000.00 3,675,000.00
Finance Costs 990,000.00 2,072,000.00
Profit Loss Before Tax -12,152,000.00 -24,639,000.00
Income Tax Expense Continuing Operations 93,000.00 2,980,000.00
Profit (loss) -12,245,000.00 -27,619,000.00
Profit Loss Attributable To Owners Of Parent -12,245,000.00 -27,619,000.00
Line item in (eur) 01.01.2021 02.01.2020 01.01.2022 02.01.2021
Profit (loss) -12,245,000.00 N/A -27,619,000.00 N/A
Adjustments For Finance Costs 990,000.00 N/A 2,072,000.00 N/A
Adjustments For Decrease Increase In Inventories 55,000.00 N/A 291,000.00 N/A
Adjustments For Increase Decrease In Trade Account Payable -1,109,000.00 N/A -1,670,000.00 N/A
Adjustments For Provisions 7,000.00 N/A -13,000.00 N/A
Adjustments For Sharebased Payments 2,549,000.00 N/A 1,270,000.00 N/A
Other Adjustments For Noncash Items -134,000.00 N/A -595,000.00 N/A
Cash Flows From Used In Operations -6,864,000.00 N/A -25,336,000.00 N/A
Interest Received Classified As Operating Activities 3,000.00 N/A 0.00 N/A
Income Taxes Paid Refund Classified As Operating Activities 104,000.00 N/A 274,000.00 N/A
Purchase Of Property Plant And Equipment Classified As Investing Activities 562,000.00 N/A 1,469,000.00 N/A
Purchase Of Intangible Assets Classified As Investing Activities 10,118,000.00 N/A 10,348,000.00 N/A
Cash Flows From Used In Investing Activities -10,693,000.00 N/A -11,817,000.00 N/A
Proceeds From Issuing Shares 103,583,000.00 N/A 77,728,000.00 N/A
Proceeds From Borrowings Classified As Financing Activities 1,000,000.00 N/A 0.00 N/A
Repayments Of Borrowings Classified As Financing Activities 63,000.00 N/A 83,000.00 N/A
Payments Of Lease Liabilities Classified As Financing Activities 479,000.00 N/A 500,000.00 N/A
Interest Paid Classified As Financing Activities 151,000.00 N/A 385,000.00 N/A
Other Inflows Outflows Of Cash Classified As Financing Activities 0.00 N/A -8,000.00 N/A
Cash Flows From Used In Financing Activities 104,025,000.00 N/A 76,472,000.00 N/A
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes 86,468,000.00 N/A 39,319,000.00 N/A
Effect Of Exchange Rate Changes On Cash And Cash Equivalents -23,000.00 N/A 3,890,000.00 N/A
Cash and cash equivalents 92,300,000.00 5,855,000.00 135,509,000.00 92,300,000.00

Please note that some sums might not add up.

Filings & Publications

2021

Report
Q1
H1
Q3
FY
Consolidated Report
/ FRA
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
25.01.24 Tompkins Patrick Executive member Buy USD 18,020.00
28.12.23 Onkelinx Bruno Executive member Buy EUR 2,035.10
18.08.23 Moreau Loïc Executive member Buy EUR 48,416.52
14.08.23 Moreau Loïc Executive member Buy EUR 28,697.60
11.08.23 Moreau Loïc Executive member Buy EUR 21,957.60
04.07.23 Wildman Ventures LLC Board Buy EUR 0.00
02.07.23 Gianello Pierre Board Buy EUR 0.00
01.07.23 Rakin Kevin Board Buy EUR 0.00
17.05.23 Khalag Hares Executive member Buy EUR 0.00
16.04.23 Subbaroyan Jeyakumar Executive member Buy EUR 0.00

Capital markets information

ISIN

BE0974358906

LEI

5493002O1ESKZ18OXR80

Sector

Health Care

Industry Group

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Sub-Industry

Health Care Equipment

Listed Stock Exchange

Euronext Brussels

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.